Biomarin Pharmaceutical Inc. (BMRN)
Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Momentum Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
BioMarin to reduce global workforce by about 225 employees
BioMarin Pharmaceutical will reduce its global workforce by about 225 employees, a filing showed on Wednesday.
Is BioMarin (BMRN) a Solid Growth Stock? 3 Reasons to Think "Yes"
BioMarin (BMRN) possesses solid growth attributes, which could help it handily outperform the market.
Why BioMarin Pharmaceutical (BMRN) is a Top Growth Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Is the Options Market Predicting a Spike in BioMarin (BMRN) Stock?
Investors need to pay close attention to BioMarin (BMRN) stock based on the movements in the options market lately.
BioMarin: Voxzogo Sales Surge Isn't Only Driving Force In 2024
BioMarin Pharmaceutical Inc. sales of Voxzogo had increased by 62% to $184 million in Q2 of 2024, compared to the same period in 2023. Potential to eventually expand the use of Voxzogo towards other indications like hypochondroplasia and idiopathic short stature. Data from the phase 1/2 study, using BMN351 for the treatment of patients with DMD amenable to exon 51 skipping, expected by the end of 2024.
Here's Why You Should Invest in BioMarin (BMRN) Stock Now
Here, we are discussing some reasons why investing in BioMarin (BMRN) stock now may turn out to be a prudent move.
Why BioMarin Pharmaceutical (BMRN) is a Top Momentum Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
BioMarin (BMRN) is an Incredible Growth Stock: 3 Reasons Why
BioMarin (BMRN) could produce exceptional returns because of its solid growth attributes.
Rare Disease-Focused BioMarin Narrows Sales Focus, Cuts Cost For Hemophilia A Gene Therapy; Lifts Annual Guidance
BioMarin Pharmaceutical Inc. BMRN announced an update on its Roctavian business to focus commercial operations on three markets: the U.S., Germany and Italy.
BioMarin (BMRN) Q2 Earnings & Sales Top Estimates, Ups '24 View
BioMarin (BMRN) posts better-than-expected second quarter earnings. It also raises its revenue and earnings guidance for full-year 2024.
BioMarin: Q2 Revenue Soars 20%
Revenue for Q2 2024 totaled $712 million, a 20% year-over-year increase. Management raised full-year 2024 guidance, reflecting the company's optimistic outlook.
